Allogene CEO David Chang to step down as Agios drug misses mid-stage trial results

Allogene announced that its chief executive, co‑founder David Chang, will leave the role after an eight‑year tenure. Chang, who previously worked at Kite Pharma, will remain on the company’s board while current chief medical officer Zachary Roberts assumes the CEO position on July 1.

The transition comes as the cell‑therapy firm continues to develop its donor‑derived lymphoma treatment, which is in late‑stage testing.

Separately, Agios Pharmaceuticals reported that its next‑generation candidate tebapivat failed to meet endpoints in a mid‑stage study of lower‑risk myelodysplastic syndromes. The company said it will not pursue that indication further, although a Phase 2 trial in another setting remains ongoing.

In related news, an AbbVie acquisition recently secured an FDA approval, underscoring ongoing activity in the sector.